Skip to main content
Erschienen in: Uro-News 10/2023

09.10.2023 | Prostatakarzinom | Zertifizierte Fortbildung

PSMA-PET/CT beim PCA

Möglichkeiten und Limitationen der Detektionsmethode

verfasst von: PD Dr. med. Felix Preisser, apl. Prof. Dr. med. Wolfgang P. Fendler, Prof. Dr. med. Derya Tilki

Erschienen in: Uro-News | Ausgabe 10/2023

zum CME-Kurs Einloggen, um Zugang zu erhalten

Auszug

Die Positronenemissionstomografie/Computertomografie des prostataspezifischen Membran-Antigens hat die Diagnostik des Prostatakarzinoms in den letzten Jahren nahezu revolutioniert. Im Vergleich zu den konventionellen Bildgebungen ist die Genauigkeit der PSMA-PET/CT deutlich höher, was eine frühere Detektion von Metastasen ermöglicht. Wie groß ist der Vorteil bei der onkologischen Tumorkontrolle?
Literatur
1.
Zurück zum Zitat Hupe MC et al. Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis. Front Oncol 2018;8:623 Hupe MC et al. Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis. Front Oncol 2018;8:623
2.
Zurück zum Zitat Hofman MS et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020;395:1208-16 Hofman MS et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020;395:1208-16
3.
Zurück zum Zitat Evangelista L et al. [68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. Eur Urol Oncol 2022;5:273-82 Evangelista L et al. [68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. Eur Urol Oncol 2022;5:273-82
4.
Zurück zum Zitat Giesel FL et al. Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. J Nucl Med Off Publ Soc Nucl Med 2018;59:1076-80 Giesel FL et al. Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. J Nucl Med Off Publ Soc Nucl Med 2018;59:1076-80
5.
Zurück zum Zitat Kuten J et al. Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. J Nucl Med Off Publ Soc Nucl Med 2020;61:527-32 Kuten J et al. Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. J Nucl Med Off Publ Soc Nucl Med 2020;61:527-32
8.
Zurück zum Zitat Maurer T et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol 2016;195:1436-43 Maurer T et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol 2016;195:1436-43
9.
Zurück zum Zitat Pyka T et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016;43:2114-21 Pyka T et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016;43:2114-21
10.
Zurück zum Zitat Franklin A et al. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. BJU Int 2021;127:71-9 Franklin A et al. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. BJU Int 2021;127:71-9
11.
Zurück zum Zitat Perera M et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer - Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol 2020;77:403-17 Perera M et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer - Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol 2020;77:403-17
12.
Zurück zum Zitat Esen T et al. 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy. Eur Urol Focus 2021;7:288-93 Esen T et al. 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy. Eur Urol Focus 2021;7:288-93
13.
Zurück zum Zitat Budäus L et al. Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol 2016;69:393-6 Budäus L et al. Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol 2016;69:393-6
14.
Zurück zum Zitat Fendler WP et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol 2019;5:856-63 Fendler WP et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol 2019;5:856-63
15.
Zurück zum Zitat Roach PJ et al. The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. J Nucl Med Off Publ Soc Nucl Med 2018;59:82-8 Roach PJ et al. The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. J Nucl Med Off Publ Soc Nucl Med 2018;59:82-8
16.
Zurück zum Zitat Sonni I et al. Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. J Nucl Med Off Publ Soc Nucl Med 2020;61:1153-60 Sonni I et al. Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. J Nucl Med Off Publ Soc Nucl Med 2020;61:1153-60
17.
Zurück zum Zitat Han S et al. Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2018;74:179-90 Han S et al. Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2018;74:179-90
18.
Zurück zum Zitat Golan S et al. Neoadjuvant 177Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-arm Phase 1 Trial. Eur Urol Oncol 2023;6:151-9 Golan S et al. Neoadjuvant 177Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-arm Phase 1 Trial. Eur Urol Oncol 2023;6:151-9
19.
Zurück zum Zitat Maurer T et al. 99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. Eur Urol 2019;75:659-66 Maurer T et al. 99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. Eur Urol 2019;75:659-66
20.
Zurück zum Zitat de Barros HA et al. Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study. Eur Urol 2022;82:97-105 de Barros HA et al. Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study. Eur Urol 2022;82:97-105
21.
Zurück zum Zitat Knipper S et al. Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery. Eur Urol Focus 2019;5:50-3 Knipper S et al. Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery. Eur Urol Focus 2019;5:50-3
22.
Zurück zum Zitat Knipper S et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery. Eur Urol 2023;83:62-9 Knipper S et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery. Eur Urol 2023;83:62-9
23.
Zurück zum Zitat Gandaglia G et al. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study. Eur Urol 2022;82:411-8 Gandaglia G et al. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study. Eur Urol 2022;82:411-8
24.
Zurück zum Zitat Gondoputro W et al. Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer. J Nucl Med Off Publ Soc Nucl Med 2022;63:1659-64 Gondoputro W et al. Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer. J Nucl Med Off Publ Soc Nucl Med 2022;63:1659-64
25.
Zurück zum Zitat Tilki D et al. Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death. J Clin Oncol 2023;41:2428-35 Tilki D et al. Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death. J Clin Oncol 2023;41:2428-35
Metadaten
Titel
PSMA-PET/CT beim PCA
Möglichkeiten und Limitationen der Detektionsmethode
verfasst von
PD Dr. med. Felix Preisser
apl. Prof. Dr. med. Wolfgang P. Fendler
Prof. Dr. med. Derya Tilki
Publikationsdatum
09.10.2023
Verlag
Springer Medizin
Erschienen in
Uro-News / Ausgabe 10/2023
Print ISSN: 1432-9026
Elektronische ISSN: 2196-5676
DOI
https://doi.org/10.1007/s00092-023-5801-0

Weitere Artikel der Ausgabe 10/2023

Uro-News 10/2023 Zur Ausgabe